You are here

  • Home
  • Archive
  • Volume 95, Issue 11
  • Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse

Article info

Article menu
Neuro-inflammation
Original research
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse

Authors

  • Benjamin P Trewin Translational Neuroimmunology Group, Kids Neuroscience Centre and Brain and Mind Centre, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Russell C Dale Clinical Neuroimmunology Group, Institute for Neuroscience and Muscle Research, Kids Research Institute at the Children's Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Jessica Qiu Translational Neuroimmunology Group, Kids Neuroscience Centre and Brain and Mind Centre, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Melissa Chu Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia PubMed articlesGoogle scholar articles
  • Niroshan Jeyakumar Translational Neuroimmunology Group, Kids Neuroscience Centre and Brain and Mind Centre, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Fionna Dela Cruz Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia PubMed articlesGoogle scholar articles
  • Jane Andersen Translational Neuroimmunology Group, Kids Neuroscience Centre and Brain and Mind Centre, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Brain Autoimmunity, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Pakeeran Siriratnam Department of Neuroscience, Monash University Central Clinical School, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Kit Kwan M Ma Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia PubMed articlesGoogle scholar articles
  • Todd A Hardy Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Department of Neurology, Concord Hospital, Concord, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Anneke van der Walt Department of Neuroscience, Monash University Central Clinical School, Melbourne, Victoria, Australia Alfred Hospital, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Jeanette Lechner-Scott The University of Newcastle, Newcastle, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Helmut Butzkueven Department of Neuroscience, Monash University Central Clinical School, Melbourne, Victoria, Australia Alfred Hospital, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Simon A Broadley School of Medicine, Griffith University, Nathan, Queensland, Australia Department of Neurology, Gold Coast University Hospital, Southport, Queensland, Australia PubMed articlesGoogle scholar articles
  • Michael H Barnett Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Brain and Mind Centre, The University Of Sydney, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Stephen W Reddel Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Department of Neurology, Concord Hospital, Concord, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Fabienne Brilot Brain Autoimmunity, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia School of Medical Science, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Tomas Kalincik Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia PubMed articlesGoogle scholar articles
  • Sudarshini Ramanathan Translational Neuroimmunology Group, Kids Neuroscience Centre and Brain and Mind Centre, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Department of Neurology, Concord Hospital, Concord, New South Wales, Australia PubMed articlesGoogle scholar articles
  • On behalf of the Australasian MOGAD Study Group
    Google scholar articles
  1. Correspondence to Associate Professor Sudarshini Ramanathan; sudarshini.ramanathan{at}sydney.edu.au
View Full Text

Citation

Trewin BP, Dale RC, Qiu J On behalf of the Australasian MOGAD Study Group, et al
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
Journal of Neurology, Neurosurgery & Psychiatry 2024;95:1054-1063.

Publication history

  • Received January 22, 2024
  • Accepted April 3, 2024
  • First published May 14, 2024.
Online issue publication 
October 16, 2024

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.